D2D Fund, Inc. – Trademark Portfolio
Entity Type: 03
D2D Fund, Inc. holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 41 (Education & Entertainment) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include FARMBLITZ. The owner is based in Allston, MA.
114 Western Avenue
Allston, MA 02134
Showing of trademarks Trademarks
Trademark Classifications
D2D Fund, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Education; providing of training; entertainment; sporting and cultural activities
Scientific and technological services; industrial analysis and research services
Insurance; financial affairs; monetary affairs; real estate affairs
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Frequently Asked Questions
How many trademarks does D2D Fund, Inc. have?
D2D Fund, Inc. has 5 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 abandoned, 1 cancelled.
What trademark classes does D2D Fund, Inc. file in?
D2D Fund, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 36 (Insurance & Financial), Class 9 (Computers & Electronics). Class 41 covers education; providing of training; entertainment; sporting and cultural activities.
What are D2D Fund, Inc.'s most well-known trademarks?
D2D Fund, Inc.'s registered trademark portfolio includes well-known marks such as FARMBLITZ. These are among 1 currently registered trademark in the portfolio.
What is D2D Fund, Inc.'s trademark registration success rate?
D2D Fund, Inc. has a 20% trademark registration rate, with 1 out of 5 resolved applications resulting in successful registration. Currently, 0 applications are pending review.